Related Experiment Video
Updated: Jun 17, 2025
Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
Identification of macrophage differentiation related genes and subtypes linking atherosclerosis plaque processing and
Da-Sheng Ning1,2,3, Zi-Qing Zhou1,2,3, Shu-Heng Zhou1,2,3
1Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangzhou 510080, PR China.
Abstract:
Metabolic syndrome(MS) is a separate risk factor for the advancement of atherosclerosis(AS) plaque but mechanism behind this remains unclear. There may be a significant role for the immune system in this process. This study aims to identify potential diagnostic genes in MS patients at a higher risk of developing and progressing to AS. Datasets were retrevied from gene expression omnibus(GEO) database and differentially expressed genes were identified. Hub genes, immune cell dysregulation and AS subtypes were identified using a conbination of muliple bioinformatic analysis, machine learning and consensus clustering. Diagnostic value of hub genes was estimated using a nomogram and ROC analysis. Finally, enrichment analysis, competing endogenous RNA(ceRNA) network, single-cell RNA(scRNA) sequencing analysis and drug-protein interaction prediction was constructed to identify the functional roles, potential regulators and distribution for hub genes. Four hub genes and two macrophage-related subtypes were identified. Their strong diagnostic value was validated and functional process were identified. ScRNA analysis identified the macrophage differentiation regulation function of F13A1. CeRNA network and drug-protein binding modes revealed the potential therapeutic method. Four immune-correlated hub genes(F13A1, MMRN1, SLCO2A1 and ZNF521) were identified with their diagnostic value being assesed, which F13A1 was found strong correlated with macrophage differentiation and could be potential diagnostic and therapeutic marker for AS progression in MS patients.
Insights
This study identifies four immune-related genes (F13A1, MMRN1, SLCO2A1, ZNF521) as potential diagnostic markers for atherosclerosis progression in metabolic syndrome patients. F13A1 shows promise for both diagnosis and therapy.
Area of Science:
- Immunology
- Genetics
- Cardiovascular Research
Background:
- Metabolic syndrome (MS) is a risk factor for atherosclerosis (AS) plaque progression, but the underlying mechanisms involving the immune system are not fully understood.
- Identifying diagnostic and therapeutic targets is crucial for managing AS in MS patients.
Purpose of the Study:
- To identify potential diagnostic genes in metabolic syndrome patients at high risk for atherosclerosis development and progression.
- To explore the role of immune cell dysregulation and identify AS subtypes associated with MS.
Main Methods:
- Utilized Gene Expression Omnibus (GEO) datasets to identify differentially expressed genes.
- Applied bioinformatics, machine learning, and consensus clustering to identify hub genes, immune cell dysregulation, and AS subtypes.
- Validated diagnostic value using nomogram and ROC analysis; explored functional roles via enrichment analysis, ceRNA networks, scRNA sequencing, and drug-protein interactions.
Main Results:
- Identified four immune-correlated hub genes: F13A1, MMRN1, SLCO2A1, and ZNF521.
- Discovered two macrophage-related AS subtypes with significant diagnostic value.
- F13A1 was strongly correlated with macrophage differentiation, indicating potential as a diagnostic and therapeutic marker.
Conclusions:
- Four novel immune-related hub genes were identified as potential diagnostic markers for AS progression in MS.
- F13A1 demonstrates significant potential as both a diagnostic and therapeutic target, particularly due to its role in macrophage differentiation.
